Literature DB >> 7024218

Marrow transplantation from donors other than HLA identical siblings.

J A Hansen, R A Clift, E M Mickelson, B Nisperos, E D Thomas.   

Abstract

As of 31 December 1979, 39 patients in Seattle have received marrow grafts from donors other than HLA genotypically identical siblings. Sixteen transplants were between siblings, 21 from a parent to a child, one from a paternal uncle, and one from an unrelated donor. Ten patients had aplastic anemia and 29 had a hematological malignancy. As of 1 February 1980, only one of the ten patients transplanted for aplastic anemia is currently alive (greater than 1048 days) with a normal marrow and without graft-versus-host disease. This surviving patient was untransfused and received marrow from an HLA phenotypically identical mother. There were five episodes of graft rejection among the ten aplastic patients. Among the 29 patients transplanted for hematological malignancy, 12 (42%) are surviving from greater than 64 to greater than 995 days. Twelve of 29 patients were transplanted while in remission and eight (75%) are alive from greater than 148 to greater than 790 days. The two most frequent causes of death were relapse of leukemia and interstitial pneumonia. Only two patients died from complications clearly related to graft-versus-host disease. Five of the surviving patients were phenotypically identical with their donor for HLA, while seven were incompatible for some HLA determinants. One patient--donor pair was incompatible for HLA-D and DR as a result of HLA-B/D recombination, and six pairs were incompatible for HLA-A and/or B.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7024218     DOI: 10.1016/0198-8859(81)90004-5

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  6 in total

1.  Marrow transplantation for leukemia.

Authors:  E D Thomas
Journal:  J Clin Immunol       Date:  1981-07       Impact factor: 8.317

2.  [Changes of therapy results in acute leukemia under different treatment schedules with special reference to gnotobiotic measures].

Authors:  H Link; H M Frauer; K Wilms; H D Waller
Journal:  Klin Wochenschr       Date:  1983-04-01

Review 3.  Genetics of allogeneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes.

Authors:  John A Hansen; Effie W Petersdorf; Ming-Tseh Lin; Steven Wang; Jason W Chien; Barry Storer; Paul J Martin
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

4.  Mixed lymphocyte reactions for individuals with phenotypic identity for specific HLA-B,DR determinants: the role of linkage disequilibrium and of specific DR and other class II determinants.

Authors:  M S Pollack; J Chin-Louie; C Callaway; M A Blanco; K Slavin; K Sullivan; R J O'Reilly; B Dupont
Journal:  J Clin Immunol       Date:  1983-10       Impact factor: 8.317

Review 5.  Modern approaches to HLA-haploidentical blood or marrow transplantation.

Authors:  Christopher G Kanakry; Ephraim J Fuchs; Leo Luznik
Journal:  Nat Rev Clin Oncol       Date:  2015-08-25       Impact factor: 66.675

6.  Haploidentical bone marrow transplantation for severe combined immunodeficiency disease using soybean agglutinin-negative, T-depleted marrow cells.

Authors:  M J Cowan; D W Wara; P S Weintrub; H Pabst; A J Ammann
Journal:  J Clin Immunol       Date:  1985-11       Impact factor: 8.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.